Brief summary for the article Antibody–drug conjugates in solid tumorsa look into novel targets

The article discusses the use of antibody-drug conjugates (ADCs) as a targeted therapy for solid tumors. ADCs are a type of cancer treatment that combines the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. The article focuses on the development of novel targets for ADCs in solid tumors, including HER2, CD70, and TROP2. The authors highlight the promising results of preclinical and clinical studies using ADCs targeting these novel targets, and discuss the potential challenges and future directions for this type of therapy.